Frequency of High-Risk Characteristics Requiring Total Thyroidectomy for 1-4cm Well-Differentiated Thyroid Cancer

被引:84
作者
Kluijfhout, Wouter P. [1 ,2 ]
Pasternak, Jesse D. [3 ]
Lim, James [1 ]
Kwon, Julie S. [1 ]
Vriens, Menno R. [2 ]
Clark, Orlo H. [1 ]
Shen, Wen T. [1 ]
Gosnell, Jessica E. [1 ]
Suh, Insoo [1 ]
Duh, Quan-Yang [1 ]
机构
[1] Univ Calif San Francisco, Dept Surg, Endocrine Surg Sect, San Francisco, CA USA
[2] Univ Med Ctr Utrecht, Dept Oncol & Endocrine Surg, Utrecht, Netherlands
[3] Univ Toronto, Dept Surg, Toronto, ON, Canada
关键词
HORMONE REPLACEMENT; LOBECTOMY; SURGERY; CARCINOMA; SURVIVAL; OUTCOMES; EXTENT;
D O I
10.1089/thy.2015.0495
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The extent of thyroidectomy for low-risk well-differentiated thyroid cancer (WDTC) remains controversial. Historically, total thyroidectomy (TT) has been recommended for WDTC >= 1 cm in size. However, recent National Comprehensive Cancer Network and American Thyroid Association guidelines recognize unilateral thyroid lobectomy as a viable alternative for 1-4 cm cancers due to their otherwise favorable prognosis, with TT remaining the preferred option for tumors with unfavorable pathological characteristics. This study sought to determine how often a completion TT would be recommended based on these guidelines if lobectomy was initially performed in patients with 1-4 cm WDTC without preoperatively known risk factors. Methods: Patients who underwent thyroidectomy for 1-4 cm WDTC (January 2000 to January 2010) were retrospectively reviewed. Patients with preoperatively known high-risk characteristics, including gross extrathyroidal extension (ETE) on preoperative imaging, clinically apparent lymph node metastases, distant metastases, history of radiation, and positive family history, were excluded. The pathology specimens from the cancer-containing lobe were evaluated for features that would lead to a recommendation for TT based on current guidelines, including aggressive histology, vascular invasion, microscopic ETE, positive margins, and any positive lymph nodes within the specimen. Results: Of 1000 consecutive patients operated for WDTC, 287 would have been eligible for lobectomy as the initial operation. The mean age in this cohort was 45 years, and 80% were women. Aggressive tall-cell variant histology was found in one patient (0.5%), angio-invasion in 34 (12%), ETE in 48 (17%), positive margins in 51 (18%), and positive lymph nodes in 49 (18%) patients. Completion TT would have been recommended in 122/287 (43%) patients. Even in those with 1-2 cm cancers, completion TT would have been recommended in 52/143 (36%) patients. Conclusions: Nearly half of the patients with 1-4 cm WDTC who are eligible for lobectomy under current guidelines would require completion TT based on pathological characteristics of the initial lobe. Surgeons, endocrinologists, and patients need to balance the relative benefits, risks, and costs of initial TT versus the possible need for reoperative completion TT.
引用
收藏
页码:820 / 824
页数:5
相关论文
共 19 条
[1]   Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival An Analysis of 61,775 Patients [J].
Adam, Mohamed Abdelgadir ;
Pura, John ;
Gu, Lin ;
Dinan, Michaela A. ;
Tyler, Douglas S. ;
Reed, Shelby D. ;
Scheri, Randall ;
Roman, Sanziana A. ;
Sosa, Julie A. .
ANNALS OF SURGERY, 2014, 260 (04) :601-607
[2]   Extent of surgery affects survival for papillary thyroid cancer [J].
Bilimoria, Karl Y. ;
Bentrem, David J. ;
Ko, Clifford Y. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Talamonti, Mark S. ;
Sturgeon, Cord .
ANNALS OF SURGERY, 2007, 246 (03) :375-384
[3]   Variables Predictive of Bilateral Occult Papillary Microcarcinoma Following Total Thyroidectomy [J].
Connor, Matt P. ;
Wells, David ;
Schmalbach, Cecelia E. .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2011, 144 (02) :210-215
[4]   Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].
Cooper, David S. ;
Doherty, Gerard M. ;
Haugen, Bryan R. ;
Kloos, Richard T. ;
Lee, Stephanie L. ;
Mandel, Susan J. ;
Mazzaferri, Ernest L. ;
McIver, Bryan ;
Pacini, Furio ;
Schlumberger, Martin ;
Sherman, Steven I. ;
Steward, David L. ;
Tuttle, R. Michael .
THYROID, 2009, 19 (11) :1167-1214
[5]   2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].
Haugen, Bryan R. ;
Alexander, Erik K. ;
Bible, Keith C. ;
Doherty, Gerard M. ;
Mandel, Susan J. ;
Nikiforov, Yuri E. ;
Pacini, Furio ;
Randolph, Gregory W. ;
Sawka, Anna M. ;
Schlumberger, Martin ;
Schuff, Kathryn G. ;
Sherman, Steven I. ;
Sosa, Julie Ann ;
Steward, David L. ;
Tuttle, R. Michael ;
Wartofsky, Leonard .
THYROID, 2016, 26 (01) :1-133
[6]   Clinical Outcomes of Patients with Papillary Thyroid Carcinoma after the Detection of Distant Recurrence [J].
Ito, Yasuhiro ;
Higashiyama, Takuya ;
Takamura, Yuuki ;
Kobayashi, Kaoru ;
Miya, Akihiro ;
Miyauchi, Akira .
WORLD JOURNAL OF SURGERY, 2010, 34 (10) :2333-2337
[7]   Hemithyroidectomy: A Meta-Analysis of Postoperative Need for Hormone Replacement and Complications [J].
Kandil, Emad ;
Krishnan, Barath ;
Noureldine, Salem I. ;
Yao, Lu ;
Tufano, Ralph P. .
ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY, 2013, 75 (01) :6-17
[8]   Occult Contralateral Carcinoma in Patients with Unilateral Papillary Thyroid Microcarcinoma [J].
Koo, Bon Seok ;
Lim, Hyun Sil ;
Lim, Young Chang ;
Yoon, Yeo-Hoon ;
Kim, Yong Min ;
Park, Yong Ho ;
Rha, Ki-Sang .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (04) :1101-1105
[9]   Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of "suspicious for papillary thyroid cancer" [J].
Leiker, Andrew J. ;
Yen, Tina W. ;
Cheung, Kevin ;
Evans, Douglas B. ;
Wang, Tracy S. .
SURGERY, 2013, 154 (06) :1307-1313
[10]   The HiLo trial: A multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer [J].
Mallick, U. ;
Harmer, C. ;
Hackshaw, A. .
CLINICAL ONCOLOGY, 2008, 20 (05) :325-326